ASH Meeting 2022 Participation

Special-Interest Sessions
Friday, December 9
9:00 AM – 12:00 PM
Location: Cypress (Marriott New Orleans Warehouse Arts District)
Research, Clinical Practice (Health Services and Quality), Workforce, Diversity, Equity, and Inclusion (DEI)
Chair: Alfred I Lee, MD, PhD
Speaker: Cecelia Calhoun, MD, MBA, MPH

Friday Satellite Symposia
Friday, December 9
11:00 AM – 2:00 PM
Location: 393-396 (Ernest N. Morial Convention Center)
Navigating a Changing Landscape Together: Gene Therapy for Hemophilia
Chair: Michael Recht, MD, PhD, MBA

Friday Satellite Symposia
Friday, December 9
11:00 AM – 2:00 PM
Location: Napoleon B (Sheraton New Orleans)
An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches
Chair: Amer M. Zeidan, MD

Friday Satellite Symposia
Friday, December 9
11:00 AM – 2:00 PM
Location: Grand Ballroom C (Sheraton New Orleans)
Practice-Changing Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma—Integrating New Treatments
Speaker: Scott F. Huntington, MD, MPH and Caron A. Jacobson, MD

Friday Satellite Symposia
Friday, December 9
3:00 – 6:00 PM
Location: Grand Ballroom C (Sheraton New Orleans)
'D' is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective
Chair: Pramod K. Mistry, MD, PhD, FRCP

Friday Satellite Symposia
Friday, December 9
3:00 – 6:00 PM  
**Location:** Celestin EFGH (Hyatt Regency New Orleans)  
*Let's Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome*  
**Speakers:** David A. Sallman, MD, **Rory M. Shallis, MD** and Eunice S. Wang, MD

**Friday Satellite Symposia**  
**Friday, December 9**  
3:00 – 6:00 PM  
**Location:** Empire B (Hyatt Regency New Orleans)  
*JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy*  
**Speakers:** Claire N. Harrison, DM and Nikolai A. Podoltsev, MD, PhD

**Annual Meeting Press Program**  
**Saturday, December 10**  
10:30 AM – 11:30 AM  
*New Drugs, New Targets*  
**Presenter:** George Goshua, MD, MSc

**Scientific Symposia**  
**Saturday, December 10**  
2:00 PM – 3:15 PM  
**Location:** 252-254 (Ernest N. Morial Convention Center)  
*Differentiation of Bipotent Progenitors to the Megakaryocytic versus Erythroid Lineages*  
**Speaker:** Diane S. Krause

**Annual Meeting Press Program**  
**Saturday, December 12**  
12:00 PM – 1:00 PM  
*No Minor Matter: Optimizing Pediatric Care*  
**Presenter:** George Goshua, MD, MSc

**Oral and Poster Abstracts**  
**Saturday, December 10**  
10:00 AM  
**Location:** 353-355 (Ernest N. Morial Convention Center)  
*602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies*  
**Authors:** Tae Kon Kim, MD, Xue Han, PhD, Qianni Hu, PhD, Carly Hedgepath, Junshik Hong, MD, Jihyun Park, Emily F Mason, MD, PhD and **Lieping Chen, MD, Ph.D.**

10:15 AM  
**Location:** 388-390 (Ernest N. Morial Convention Center)  
*903. Health Services and Quality—Myeloid Malignancies I*
130 Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia

Authors: Jan Philipp Bewersdorf, MD, Kishan K Patel, MD MHS, George Goshua, MD, MSc, Rory M. Shallis, MD, Nikolai A. Podoltsev, MD, PhD, Maximilian F. Stahl, MD, Jessica M. Stempel, MD, Eytan Stein, MD, Scott F. Huntington, MD, MPH, and Amer M. Zeidan, MD

Saturday, December 10
10:15 AM
Location: Great Hall AD (Ernest N. Morial Convention Center)


Moderators: Alfred I Lee, MD, PhD

Sunday, December 11
6:00 - 8:00 PM

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II

Authors: Amin H Nassar, MD, Stefan Groha, PhD, Edward El-am, MD, Antoine Bejjani, MD, Talal El Zarif, MD, Tarek H. Mouhieddine, MD, Sarah Abou Alaiwi, Elio Adib, Kimmie Ng, MD, Jean M. M Connors, MD, Alfred I Lee, MD, PhD, and Alexander Gusev, PhD

Monday, December 12
10:30 AM – 12:00 PM
Location: Ernest N. Morial Convention Center

Lymphoid Oncogenesis: Basic Program: Oral and Poster Abstracts

Moderator: Shalin Kothari, MD

Monday, December 12, 2022
6:00 - 8:00 PM
Location: Ernest N. Morial Convention Center

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma – a Bridge to Transplant and an Effective Salvage for the Unfit

Authors: Matko Kalac, MD, PhD, Salvia Jain, MD, Constantine S. Tam, MD, MBBS, Mendel Goldfinger, MD, Zhengrui Xiao, MD, Francesca Montanari, MD, Bryan D. Huber, MD, Jennifer A. Kanakry, MD, Owen A. O'Connor, MD, PhD, and Enrica Marchi, MD, PhD

Education Programs

Saturday, December 10
2:00 – 3:15 PM
Location: Great Hall AD (Ernest N. Morial Convention Center)

Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations

Chair: Alfred I Lee, MD, PhD

Saturday, December 10
2:00 – 3:15 PM
**Location:** Great Hall AD (Ernest N. Morial Convention Center)  
*Thrombosis Questions from the Inpatient Wards*  
**Speaker:** Alfred I Lee, MD, PhD

**Saturday, December 10**  
2:00 - 3:15 PM  
**Location:** Great Hall AD (Ernest N. Morial Convention Center)  
*Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations*  
**Presenter:** Layla N Van Doren, MD

**Saturday, December 10**  
5:30 – 7:30 PM  
**Location:** Hall D (Ernest N. Morial Convention Center)  
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I  
1424 Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia  
**Authors:** Amer M. Zeidan, MD, Wei-Han Cheng, PhD, Rajesh Kamalakar, MS, Catherine Miller, PharmD, Cat N. Bui, PharmD, Melissa Montez, PharmD, Tracy Yee, PhD, MPH, Zheng Wu, MS and **Scott F. Huntington, MD, MPH**

**Saturday, December 10**  
5:30 – 7:30 PM  
**Location:** Hall D (Ernest N. Morial Convention Center)  
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I  
2170 Harmonizing the Annotation of Hematopoietic Populations in Single-Cell Atlases with the Cell Marker Accordion  
**Authors:** Emma Busarello, Zuhairia Ibnat, Giulia Biancon, PhD, Jennifer VanOudenhove, PhD, Fabio Lauria, PhD, Gabriella Viero, PhD, Stephanie Halene, MD and **Toma Tebaldi, PhD**

**Saturday, December 10**  
5:30 – 7:30 PM  
**Location:** Hall D (Ernest N. Morial Convention Center)  
901. Health Services and Quality—Non-Malignant Conditions: Poster I  
2201 Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology Training  
**Authors:** Anna Kress, MD, Benjamin Lu, MD, Ayesha Butt, MBBS, Jana Christian, MD, Nikolai A. Podoltsev, MD, PhD, Michael Hurwitz, MD, PhD, Sarah Goldberg, MD, Barbara Burtness, Iris Isufi, MD, Darin Latimore, Alfred I Lee, MD, PhD, and Pamela Kunz, MD

**Saturday, December 10**
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I
1760 Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents in a Real-World Setting
Authors: Amer M. Zeidan, MD, Victoria Divino, BA, Mitch DeKoven, MHSA, Elizabeth Wang, MS, Justin Chen, BPharm, MHS, Tehseen Salimi, MD, MHA and Robert S. Epstein, MD, MS

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I
1770 Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndrome (MDS)
Authors: Amer M. Zeidan, MD, Amy E. DeZern, MD, Uma Borate, MD, Krissy Kobata, Susan E. Ide, PhD, John Sabo, Pedro Marques Ramos, PhD, Haiying Sun, Roger M. Lyons, MD and Guillermo Garcia-Manero, MD

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
906. Outcomes Research—Myeloid Malignancies: Poster I
2309 Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma
Authors: Rong Wang, PhD, Natalia Neparidze, MD, Xiaomei Ma, PhD, Graham A Colditz, MD, DrPH, Su-Hsin Chang, PhD and Shi-Yi Wang, MD, PhD

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
2024 Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
Authors: Abu-Sayef Mirza, MD, MPH, Chitra Hosing, MD, Francine M. Foss, MD, Soyoung Kim, PhD, Amy Moskop, MD, MS, Temitope Oloyede, Sairah Ahmed, MD, Peiman Hematti, MD, Cameron J. Turtle, MBBS, PhD, Marcelo C Pasquini, MD, MS and Lohith Gowda, MD

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I
1152 Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset
Authors: Brian Hu, MS, Ph, Martin Chandler, BS, Matthew Manuel, MS, PhD, Jorge Caicedo, MD, Michael Denne, PharmD, Bruce Ewenstein, MD, PhD, Ali Mokdad, MD, PhD, MBA, Shan Xing, PharmD, PhD and Michael Recht, MD, PhD, MBA

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)

113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster I
1048 Colchicine Reduces Inflammation in a Humanized Mouse Model of Sickle Cell Disease
Authors: Raghda T Fouda, MD, PhD, Hemanth M Cherukury, MS, Stacy B Kiven, BSc, Natalie Garcia, BS, Donovan A Argueta, PhD, Kalpna Gupta, PhD and John D Roberts, MD

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I
1165 Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset
Authors: Martin Chandler, BS, Jessica Charlet, PhD, MSc, BSc, Thomas Moulton, MD and Michael Recht, MD, PhD, MBA

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
1346 GSK3β Inhibition Is a Unique Vulnerability in Lymphoid Malignancies
Authors: Kadriye Nehir Cosgun, PhD, Huda Jumaa, PhD, Mark E. Robinson, PhD, Lai N. Chan, PhD, Jaewoong Lee, PhD, Kohei Kume, PhD, David Fonseca Arce, Julia Jellusova, PhD, and Markus Müschen, MD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

603. Lymphoid Oncogenesis: Basic: Poster I
1303 IFITM3 Acts As a PIP3 Scaffold in TCR-PI3K Signaling
Authors: Andrew Takeda, Jaewoong Lee, PhD, Tim Wartewig, MD, PhD, Alberto Bigogno, David Fonseca Arce and Markus Müschen, MD

Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)

503. Clonal Hematopoiesis, Aging and Inflammation: Poster I
1231 The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
Saturday, December 10
5:30 – 7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I

1107 Loss of the Nuclear Receptor Pparγ Primes T Effector (TEFF) Differentiation of Antigen-Specific CD8+ T Cells

Authors: Rushil Shah, Xanthi-Leda Katopodi, MS, Anthos Christofides, MD, Rinku Pal, MS, Ioannis Vlachos, PhD, Nikolaos Patsoukis, PhD and Vassiliki A Boussiotis, MD, PhD

Special-Interest Sessions

Sunday, December 11
7:30 AM – 9:30 AM
Location: Cypress (Marriott New Orleans Warehouse Arts District)

Burnout and Faculty Engagement
Speaker: Alfred I Lee, MD, PhD

Mentorship
Speaker: Anish V. Sharda, MBBS

Getting Young Hematologists Interested in Classical Hematology
Speaker: Alfred I Lee, MD, PhD

Sunday, December 11
11:30 AM
Location: Hall D (Ernest N. Morial Convention Center)

603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis

707 A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell Signaling
Sunday, December 11
12:15 PM
Location: 265-268 (Ernest N. Morial Convention Center)
637. Myelodysplastic Syndromes – Clinical and Epidemiological IV
559 Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Moderator: Rory M. Shallis, MD
Authors: Valeria Santini, MD, PhD, Uwe Platzbecker, MD, Pierre Fenaux, Aristoteles Giagounidis, MD, Yasushi Miyazaki, MD, Mikkael A. Sekeres, MD, Zhijian Xiao, MD&PhD, Guillermo Sanz, MD, PhD, Marlies Van Hoef, Fei Ma, Sabine Hertle, Pedro Marques Ramos, PhD and Amer M. Zeidan, MD

Sunday, December 11
12:15 PM
Location: 275-277 (Ernest N. Morial Convention Center)
602. Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation
530 U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid Malignancies
Authors: Giulia Biancon, PhD, Emma Busarello, Mark D Lessard, MS, Edward Courvan, PhD, Dahyana Arias Escayola, PhD, Jennifer VanOudenhove, PhD, Veronica Lee, Mathew Krick, Joerg Bewersdorf, PhD, Karla M Neugebauer, PhD, Toma Tebaldi, PhD and Stephanie Halene, MD

Sunday, December 11
12:00 – 1:30 PM
Location: R06-R09 (Ernest N. Morial Convention Center)
904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies & Outcomes
579 Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study
Authors: Sobenna A George, MD, Anirudh Veludhandi, BS, Yijin Xiang, MPH, Elizabeth Stenger, MD, MSc, Staci D. Arnold, MD, MBA, MPH, Akanksha Mehta, MD, David A Schirmer, MD, Jessica B Spencer, MD, MSc, Gregory M Guilcher, MD, BSc, FRCP, Monica Bhatia, MD, Allistair Abraham, MD, Veronica Gomez-Lobo, MD, Lakshmanan Krishnamurti, MD and Lillian R Meacham, MD

Sunday, December 11
1:00 PM
Location: R06-R09 (Ernest N. Morial Convention Center)
904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies & Outcomes
581 Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States

Authors: George Goshua, MD, MSc, Cecelia Calhoun, MD, MBA, MPH, Vivien Cheng, MPH, Lyndon James, MD MPH, Andrea Luviano, MD MPH, Lakshmanan Krishnamurti, MD and Ankur Pandya, PhD

Sunday, December 11
1:15 PM
Location: R06-R09 (Ernest N. Morial Convention Center)

904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies & Outcomes
582 Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study

Authors: Lillian R Meacham, MD, Anirudh Veludhandi, BS, Yijin Xiang, MPH, Elizabeth Stenger, MD, MSc, Staci D. Arnold, MD, MBA, MPH, Akanksha Mehta, MD, Lydia H. Pecker, MD, Michael Hsieh, MD, PhD, Jacqueline Y Maher, MD and Lakshmanan Krishnamurti, MD

General Sessions
Sunday, December 11
2:00 – 4:00 PM
Location: Hall E (Ernest N. Morial Convention Center)

Plenary Introducer
Speaker: Patrick G. Gallagher, MD

Sunday, December 11
5:00 PM
Location: 391-392 (Ernest N. Morial Convention Center)

201. Granulocytes, Monocytes, and Macrophages I
585 SHP-2 Regulates Myeloid Cell Differentiation, Anti-Tumor Responses and Innate Immune Memory

Authors: Anthos Christofides, MD, Xanthi-Leda Katopodi, MS, Carol Cao, Dimitra Karagkouni, PhD, Konstantinos Aliazis, PhD, Sasitorn Yenyuwadee, MD, Rinku Pal, MS, John Asara, PhD, Ioannis Vlachos, PhD3, Nikolaos Patsoukis, PhD and Vassiliki A Boussiotis, MD, PhD

Sunday, December 11
5:15 PM
Location: 295-296 (Ernest N. Morial Convention Center)

670 Cost-Effectiveness of Caplacizumab without First-Line Therapeutic Plasma Exchange Vs. Standard-of-Care for Patients with Immune Thrombotic Thrombocytopenic Purpura: Setting Future Clinical Trial Thresholds

Authors: Ayesha Butt, MBBS, Alfred I Lee, MD, PhD and George Goshua, MD, MSc

Sunday, December 11
5:30 PM
Location: 353-355 (Ernest N. Morial Convention Center)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia

599 Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Authors: Talha Badar, MD, Ehab L. Atallah, MD, Rory M. Shallis, MD, Antoine N. Saliba, MD, Maximilian F. Stahl, MD, Jan Philipp Bewersdorf, MD, Justin Grenet, MD, Anand Ashwin Patel, MD, Yasmin Abaza, MD, Guru Subramanian Guru Murthy, MBBS, Adam S Duvall, MD, Madelyn Burkart, MD, Neil Palmisiano, MD, MS, Michal Jakub Kubiat, MD, Vamsi K. Kota, MD, Shira Dinner, MD, Aaron D Goldberg, MD, PhD and Mark R. Litzow, MD

Sunday, December 11
5:45 PM
Location: R06-R09 (Ernest N. Morial Convention Center)

637. Myelodysplastic Syndromes – Clinical and Epidemiological II

462 Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program

Authors: Amer M. Zeidan, MD, Caroline Fradette, PhD, Anna Rozova, MD, Noemi Toiber Temin, MA and Fernando Tricta, MD

Sunday, December 11
5:45 PM
Location: 393-396 (Ernest N. Morial Convention Center)


618 Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Authors: Francine M. Foss, MD, Youn H. Kim, MD, H. Miles Miles Prince, MD, Timothy M. Kuzel, MD, Costas K. Yannakou, MBBS, Chean Eng Ooi, PhD, Dongyuan Xing, PH D, Nicholas Sauter, MD, Preeti Singh, MD, Myron Czuczman, MD and Madeleine Duvic, MD

Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II

3087 Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome

Authors: Tariq Kewan, MD, Waled Bahaj, MD, Mai Aly, MD, BSc, MS, Arda Durmaz6, Olisaemeka Ogube, Hetty E. Carraway, MD, MBA8, Abhay Singh, MD, MPH, Suresh Kumar Balasubramanian, MD, Mikkael A. Sekeres, MD, Valeria Visconte, PhD, Carmelo Gurnari, MD and Jaroslaw P. Maciejewski, MD, PhD, FACP

Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II
Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Authors: Sabrina L. Browning, MD, Yuxin Liu, MD, Terri L. Parker, MD, Noffar Bar, MD, Tara Anderson, PA-C, Madhav Dhodapkar, MBBS, Stuart Seropian, MD, Stephanie Halene, MD, Mina L Xu, MD, Ria Syam, BS, Elan Gorshein, DO, JD, MPH, Autumn DiAdamo, BS, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Francesca Montanari, MD, Andrew Lischuk, MD, Wei Wei, MD, Andrew Haims, MD and Natalia Neparidze, MD

Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Authors: Wilson I. Gonsalves, MD, Natalia Neparidze, MD, Jacob B. Allred, Shaji K Kumar, MD, Joel M. Reid, PhD, Geoffrey Shapiro, MD, PhD, Brian A. Costello, MD, Richard Piekarz, MD, PhD, MS, BA, Rachid C. Baz, MD and Srinivas Devarakonda, MD

Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Authors: Yuxin Liu, MD, Sabrina L. Browning, MD, Jennifer VanOudenhove, PhD, Giulia Biancon, PhD, Noffar Bar, MD, Terri L. Parker, MD, Tara Anderson, PA-C, Madhav Dhodapkar, MBBS, Stuart Seropian, MD, Stephanie Halene, MD, Mina L Xu, MD, Elan Gorshein, DO, JD, MPH, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Francesca Montanari, MD, Andrew Lischuk, MD, Andrew Haims, MD, Wei Wei, MD and Natalia Neparidze, MD

Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

Authors: Adam J. Olszewski, MD, Scott F. Huntington, MD, MPH, Rajat Bannerji, MD, PhD, Thomas A. Ollila, MD, Jessica McMahon, RN-BSN, OCN and Patrycja M Dubielecka, PhD

Sunday, December 11
6:00 – 8:00 PM
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II

**2584 Complex Formation between FANCD2 and the Splicing Factor SRSF1 Helps Prevent R-Loop Accumulation through mRNA Export Regulation**

Authors: Anne Olazabal Herrero, Fengshan Liang, PhD, Arijit Dutta, PhD, Yuxin Huang, PhD, Zhuobin Liang, PhD, Abhishek K Gupta, PhD, Li Lan, Manoj M Pillai, MD, Patrick Sung, PhD and Gary M. Kupfer, MD

**Sunday, December 11**
**6:00 – 8:00 PM**

Location: Hall D (Ernest N. Morial Convention Center)

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

**2779 Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)**

Authors: Jan Philipp Bewersdorf, MD, Vanessa Hasle, Rory M. Shallis, MD, Ethan G. Thompson, PhD, Daniel Lopes de Menezes, PhD, Shelonitda Rose, MD, Isaac W. Boss, PhD, Stephanie Halene, MD, Torsten Haferlach, MD, Brian Fox and Amer M. Zeidan, MD

**Sunday, December 11**
**6:00 – 8:00 PM**

Location: Hall D (Ernest N. Morial Convention Center)

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

**2795 Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhigh but Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age**

Authors: Eric S. Winer, MD, Yael Flamand, MS, Rory M. Shallis, MD, Jessica M. Stempel, MD, Aaron D Goldberg, MD, PhD, Maximilian F. Stahl, MD, Anand Ashwin Patel, MD, Adam S Duvall, MD, Yasmin Abaza, MD, Timothy Seijung Oh, MD, Karen Ma, MD, Talha Badar, MD, Mark R. Litzow, MD, Vamsi Kota, MD, Danielle Bradshaw, MD, Hari S. Raman, MD, Marlise R. Luskin, MD, Richard M. Stone, MD and Daniel J. DeAngelo, MD, PhD

**Sunday, December 11**
**6:00 – 8:00 PM**

Location: Hall D (Ernest N. Morial Convention Center)

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II

**2927 Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302**

Authors: H. Miles Miles Prince, MD, Larisa J Geskin, MD, Oleg E Akilov, MD, Timothy M. Kuzel, MD, Christiane Querfeld, MD, PhD, Chean Eng Ooi, PhD, Dongyuan Xing, PH D, Nicholas Sauter, MD, Preeti Singh, MD, Myron Czuczman, MD and Francine M. Foss, MD

**Sunday, December 11**
**6:00 – 8:00 PM**
**Location:** Hall D (Ernest N. Morial Convention Center)

**401. Blood Transfusion: Poster II**

**2520 SRSF2 or TET2 Mutations in Patients with MDS Predict Increased Red Blood Cell Alloimmunization**

**Authors:** Juliana Guarente, MD, Jeanne E. Hendrickson, MD, Fangyong Li, MS, MPH, Stephen Parziale, MSc, BSc, Christopher A. Tormey, MD and Alexa J. Siddon, MD

Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**636. Myelodysplastic Syndromes—Basic and Translational: Poster II**

**3060 Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia**

**Authors:** Tariq Kewan, MD, Arda Durmaz, Waled Bahaj, MD, Carmelo Gurnari, MD, Hussein Awada, Olisaemeka Ogbeu, Ramsha Ahmed, MD, Simona Pagliuca, MD, PhD, Hassan Awada, MD, Yasuo Kubota, MD, PhD, Minako Mori, MD, PhD, BEN Ponvilawan, MD, Bayan Al-Share, MD, Bhumiika J. Patel, MD, Hetty E. Carraway, MD, MBA, Jacob Scott, Suresh Kumar Balasubramanian, MD, Taha Bat, MD, Yazan F. Madanat, MD, Mikkael A. Sekeres, MD, Torsten Haferlach, MD, Valeria Visconte, PhD and Jaroslaw P. Maciejewski, MD, PhD, FACP

Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**603. Lymphoid Oncogenesis: Basic: Poster II**

**2622 Divergent MYC- and BCL6-Driven Metabolic Programs Enable Dynamic Regulation of Cell Biomass in B-Cell Malignancies**

**Authors:** Kohei Kume, PhD, Zhengshan Chen, MD-PhD, Lai N. Chan, PhD, Mark E. Robinson, PhD, Etienne Leveille, MD, Jaewoong Lee, PhD, Kadiyie Nehir Cosgun, PhD, David Fonseca Arce, Dhruv Khanduja, Lars Klemm and Markus Muschen, MD

Sunday, December 11
6:00 – 8:00 PM
Location: 393-396 (Ernest N. Morial Convention Center)

**603. Lymphoid Oncogenesis: Basic: Mechanisms in Leukemogenesis**

**415 Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia**

**Authors:** Zhenhua Chen, PhD, Keren Zhou, Jianhuang Xue, Andrew Small, Gang Xiao, PhD, Le Xuan Truong Nguyen, PhD, Zheng Zhang, Emily Prince, Hengyou Weng, Huilin Huang, Zichong Zhao, Ying Qing, Chao Shen, PhD, Li Han, Brandon Tan, Wei Li, Rui Su, PhD, Hanjun Qin, PhD, Yangchan Li1, Dong Wu, Zhaohui Gu, PhD, Vu N Ngo, PhD, Xin He, MD, Jianfei Chao, Keith Leung, Kitty Wang, Lei Dong, Xi Qin, Zhenming Cai1, Yue Sheng, PhD, Yu Chen, Xiwei Wu, PhD, Bin Zhang, PhD, Yanhong Shi, Guido Marcucci, MD, Zhijian Qian, Ph.D, Mingjiang Xu, MD, PhD, Markus Muschen, MD, Xiaolan Deng and Jianjun Chen, PhD

Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II**
**2660 CD25 As Feedback Regulator of Oncogenic TCR Signaling in T-Cell Lymphoma**

Authors: Ruifeng Sun, BS, Jaewoong Lee, PhD, Tim Wartewig, MD, PhD, Mark E. Robinson, PhD, Alberto Bigogno, David Fonseca Arce, Abu-Sayef Mirza, MD, MPH2, Andrew Takeda, Lars Klemm, Vivasvan Vyakunta, Brian Shy, Alexander Marson, MD PhD and Markus M"uschen, MD

Sunday, December 11
6:00 – 8:00 PM

**621. Lymphomas: Translational—Molecular and Genetic: Poster II**

2638 Extranaodral Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Authors: Jennifer R Chapman-Fredricks, MD, Devang Thakkar, Juan Pablo Alderuccio, MD, Kikkeri N Naresh, MD, MBBS, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Mina L Xu, MD, Nathan Paulson, Jean L. Koff, MD, MSc, David L. Jaye, MD, Jonathon B. Cohen, MD, MS, Anne Orved Gang, MD, PhD, Rebecca J Leeman-Neill, MD, PhD, Tushar Dave, MS, Lanie Happ, PhD, Cassandra Love, Sasan Zandi, MD, PhD, Hina Naushad, MD, Emily F Mason, MD, PhD, Abner Louissaint Jr., MD, PhD, Haley Martin, Choon Kiak Ong, PhD, Raju Pillai, MD, Mette Ø Pedersen, MD PhD, C. Cameron Yin, MD, PhD, William Choi, MBBS, MRCP, Rex Kwok Him Au-Yeung, MBBS, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Amy Chadburn, MD, Vincent Sarno, Matthew McKinney, MD, Payal Sojitra, MD, Andrew G Evans, MD, PhD, Amir Behdad, MD, Carlos Galvez, MD, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Magdalena Czader, MD, PhD, Jiong Yan, Sandeep S. Dave, MD, MS and Izidore S. Lossos, MD

Sunday, December 11
6:00 – 8:00 PM

**613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II**

2699 Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Authors: Talha Badar, MD, Ehab L. Atallah, MD, Antoine N. Saliba, MD, Rory M. Shallis, MD, Maximilian F. Stahl, MD, Jan Philipp Bewersdorf, MD, Guillerhme Sacchi De Camargo Correia, MD, Anand Ashwin Patel, MD, Yasmin Abaza, MD, Guru Subramanian Guru Murthy, MD, Adam S Duvall, MD, Madelyn Burkart, MD, Neil Palmisiano, MD, MS, Danielle Bradshaw, MD, Vamsi K. Kota, MD, Shira Dinner, MD, Aaron D Goldberg, MD, PhD and Mark R. Litzow, MD

Sunday, December 11
6:00 – 8:00 PM

**637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II**

3098 Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Authors: Uwe Platzbecker, MD, Valeria Santini, MD, PhD, Rami S. Komrokji, Amer M. Zeidan, MD, Guillermo Garcia-Manero, MD, Rina Buckstein, Esther Natalie Oliva, MD, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, PhD, MSc, Dimana Miteva and Pierre Fenaux
Sunday, December 11
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

905. Outcomes Research—Lymphoid Malignancies: Poster II
3611 Cumulative Incidence and Outcomes of Transformed Follicular Lymphoma in the United States, 2000-2018
Authors: John L Vaughn, MD, MS and Narendranath Epperla, MD, MS

Spotlight Session
Monday, December 12
10:30 AM – 11:45 AM
Location: 295-296 (Ernest N. Morial Convention Center)
AGAINST (most/all patients with Acquired TTP should receive caplacizumab)
Speaker: George Goshua, MD, MSc

Spotlight Session
Scientific Program
Monday, December 12
2:45 PM – 4:00 PM
Location: 208-210 (Ernest N. Morial Convention Center)
Spatial Multi-Omics Profiling of Human Lymphoid and Hematopoietic Tissues
Speaker: Rong Fan, PhD

Monday, December 12
2:45 PM
Location: 243-245 (Ernest N. Morial Convention Center)
637. Myelodysplastic Syndromes – Clinical and Epidemiological I
853 Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Authors: Amer M. Zeidan, MD, Kiyoshi Ando, MD, PhD, Odile Rauzy, Mehmet Turgut, MD, Ming-Chung Wang, MD, Roberto Cairoli, Hsin-An Hou, MD, PhD, Yok-Lam Kwong, MD, Montserrat Arnan Sangerman, PhD, Stef Meers, Vinod A. Pullarkat, MD, Valeria Santini, MD, PhD, Kamel Malek, Flavia Kierman, Jiaying Lyu, Pedro Marques Ramos, PhD, Pierre Fenaux, Yasushi Miyazaki, MD and Uwe Platzbecker, MD

Monday, December 12
3:00 PM
Location: 243-245 (Ernest N. Morial Convention Center)
637. Myelodysplastic Syndromes – Clinical and Epidemiological I
854 Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
Authors: Michael R. Savona, MD, James K McCloskey, MD, Elizabeth A. Griffiths, MD, Karen Yee, MD, Amer M. Zeidan, MD, Aref Al-Kali, MD, Joachim Deeg, MD, Prapti Patel, MD, Mitchell Sabloff, MSc, MD, FRCP, Mary-Margaret Keating, MD, FRCP, Kim-Hien Dao, DO, Nancy Zhu, MD, Nashat Y. Gabrail, MD, Salman Fazal, MD, Joseph J. Maly, MD, Olatoyosi Odenike, MD, Hagop Kantarjian, MD, Amy E. DeZern, MD, Casey L. O’Connell, MD, Gail J. Roboz, MD, Lambert Busque, MD, Rena Buckstein, Harshad Amin, MD, Jasleen K. Randhawa, MD, Brian Leber, MD, Aram Oganesian,
PhD, Winny Chan, PharmD, Yong Hao, MD, PhD, Mohammad Azab, MD and Guillermo Garcia-Manero, MD

Monday, December 12
3:15 PM
Location: New Orleans Theater C (Ernest N. Morial Convention Center)
901. Health Services and Quality—Non-Malignant Conditions: Level Up! Taking Quality Care to the Next Level in Sickle Cell Disease
885 A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease
Authors: George Goshua, MD, MSc, Ronald G. Hauser, MD, Chris Tormey, MD, Ankur Pandya, PhD and Jeanne E. Hendrickson, MD

Education Program
Monday, December 12
4:30 PM – 5:45 PM
Location: New Orleans Theater AB (Ernest N. Morial Convention Center)
Negotiation, It’s More Than Just the Money
Speaker: Cecelia Calhoun, MD, MBA, MPH

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
4671 Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel
Authors: Abu-Sayeef Mirza, MD, MPH, Alexander Pine, MD, PhD, Yusuf Rasheed, Ramzi Hamouche, MD, Etienne Leveille, MD, George Goshua, MD, MSc, Sean Gu, MD, PhD, Yuxin Liu, MD, Jennifer VanOudenhove, PhD, Noffar Bar, MD, Natalia Neparidze, MD, Francine M. Foss, MD, Lohith Gowda, MD, Iris Isufi, MD, Stephanie Halene, MD, Alfred I Lee, MD, PhD and Stuart Seropian, MD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
4091 A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
Authors: Jan Philipp Bewersdorf, MD, Rory M. Shallis, MD, Elad Sharon, MD, MPH, Anne Caldwell, Wei Wei, MD, Abdulraheem Yacoub, MD, Yazan F. Madanat, MD, Joshua F. Zeldner, MD, Jessica K. Altman, MD, Olatoyosi Odenike, MD, Swaroopa Yerrabothala, MD, Tibor Kovacsovics, MD, Nikolai A. Podoltsev, MD, PhD, Stephanie Halene, MD, Richard F. Little, MD, MPH, Richard Piekarz, MD, PhD, MS, BA, Steven D. Gore, MD, Tae Kon Kim, MD and Amer M. Zeidan, MD

Monday, December 12
6:00 – 8:00 PM
3753 Plasma Proteomic Profiling Illustrates Endothelial and Complement Signature in Patients with Alcohol-Associated Cirrhosis

Authors: Cecily Allen, MD, Ayesha Butt, MBBS, Xiwen Zhao, Fangyong Li, PhD, Parveen Bahel, C-Hong Chang, PhD, Hyung Chun, MD, Sean Gu, MD, PhD, John Hwa, MD, Sofia Jakab, MD, Bonnie Chen, Guadalupe Garcia-Tsao, MD, Henry Rinder, MD, Uyen To, MD, Matthew McConnell, MD, Alfred I Lee, MD, PhD and Alexander Pine, MD, PhD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
4017 Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Authors: Jan Philipp Bewersdorf, MD, Vanessa Hasle, Rory M. Shallis, MD, Ethan G. Thompson, PhD, Daniel Lopes de Menezes, PhD, Shelonitda Rose, Isaac W. Boss, PhD, Stephanie Halene, MD, Torsten Haferlach, MD, Brian Fox and Amer M. Zeidan, MD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III
4022 Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)

Authors: Rory M. Shallis, MD, Julian Weiss, Eric S. Winer, MD, Talha Badar, MD, Alok Swaroop, Peter Doukas, Emily Geramita, MD, PhD, Henry Le, Sonal Agarwal, PharmD, Man Yee Merl, Annie Im, MD, Yasmin Abaza, MD, Mark R. Litzow, MD and Nikolai A. Podoltsev, MD, PhD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

603. Lymphoid Oncogenesis: Basic: Poster III
3936 Repressive β-Catenin-Ikaros Complexes Are Essential to Prevent Clonal Evolution of Human Lymphopoiesis

Authors: Kadijie Nehir Cosgun, PhD, Wei Liu, Mark E. Robinson, PhD, David Fonseca Arce, Jennifer VanOudenhove, PhD, Alberto Bigogno, Richard Flavell, PhD, Stephanie Halene, MD and Markus Müschen, MD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

603. Lymphoid Oncogenesis: Basic: Poster III
3943 Structural Elements of the BCR Determine Permissiveness to Oncogenic RAS-Driven B-Cell Transformation

Authors: Lai N. Chan, PhD, Mark E. Robinson, PhD, Kadijie Nehir Cosgun, PhD, Xiaohui Yu, Etienne Leveille, MD, Huimin Geng, PhD and Markus Müschen, MD
Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**906. Outcomes Research—Myeloid Malignancies: Poster III**

**4943 Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib**

Authors: Jessica M. Stempel, MD, Rong Wang, PhD, Rory M. Shalis, MD, Scott F. Huntington, MD, MPH, Amer M. Zeidan, MD, Natalia Neparidze, MD, Mengyang Di, MD, PhD, Xiaomei Ma, PhD and Nikolai A. Podoltsev, MD, PhD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**906. Outcomes Research—Myeloid Malignancies: Poster III**

**4956 Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By Baseline Transfusion Status**

Authors: Amer M. Zeidan, MD, Carmen Ng, PhD, Archibong Yellow-Duke, PharmD, Neil Lamarre, PhD, Wei-Han Cheng, PhD and Esprit Ma, MPH

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III**

**4395 Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)**

Authors: Amer M. Zeidan, MD, Karen Mosher, Sonia Souza, PhD, Beloo Mirakhur, MD, PhD, Harold N. Keer, MD, PhD and Jason A. Taylor, MD, PhD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**906. Outcomes Research—Myeloid Malignancies: Poster II**

**3627 Streamline – Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis**

Authors: Amer M. Zeidan, MD, Santosh Gautam, PhD, Rebekah Yu, MS, Ziyu Lan, MPH, David L. Grinblatt, Dina ElSouda, MSc, MSIA, James Spalding, PharmD, MBA, Alana Block, PharmD, Maelys Touya, PharmD and Bhavik J. Pandya, PharmD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

**721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III**

**4692 Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease**

Authors: Aron Flagg, MD, Rohaum Hamidi, MD, Yanhong Deng, PhD, Niketa C. Shah, MD, Lakshmanan Krishnamurti, MD and Zili He, MS

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
905. Outcomes Research—Lymphoid Malignancies: Poster III
4899 Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis
Authors: Mengyang Di, MD, PhD, Jessica B Long, MPH, Shalin K. Kothari, MD, Tarsheen Sethi, MD, MBBS, MSc, Amer M. Zeidan, MD, Nikolai A. Podoltsev, MD, PhD, Rory M. Shallis, MD, Rong Wang, PhD, Jessica M. Stempel, MD, Xiaomei Ma, PhD and Scott F. Huntington, MD, MPH

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
902. Health Services and Quality—Lymphoid Malignancies: Poster III
4859 Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis
Authors: Mengyang Di, MD, PhD, Jessica B Long, MPH, Iris Isufi, MD, Francine M. Foss, MD, Stuart Seropian, MD, Cary P Gross, MD and Scott F. Huntington, MD, MPH

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
902. Health Services and Quality—Lymphoid Malignancies: Poster II
3542 Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study
Authors: Scott F. Huntington, MD, MPH, Enrico De Nigris, Justin Puckett, BA, Sachin Kamal-Bahl, PhD, Mohammed Z.H. Farooqui, DO, Katherine Elizabeth Ryland, PhD, Eric Sarpong, PhD, Xiaoqin Yang, PhD and Jalpa Doshi, PhD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
903. Health Services and Quality—Myeloid Malignancies: Poster III
4872 Understanding What Matters to Myelodysplastic Syndrome Patients – a Study of Preferences for Treatments with Hypomethylating Agents
Authors: Amer M. Zeidan, MD, Sophie (jui-Hua) Tsai, MD, MS, Milad Karimi, PhD, MS, Jordana Schmier, MA, Sayeli Jayade, MPH, Evangelos Zormpas, PhD, MS, Audrey Hassan, Desiree Ruiters, Cindy Anthony, Kala Hill, MSc, Tim Wert and Marc Botteman, MS, MA

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
4135 BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation
**Authors:** Lai N. Chan, PhD, Christian Hurtz, PhD, Mark E. Robinson, PhD, Etienne Leveille, MD, Huimin Geng, PhD, Rebecca Caeser, PhD, Liang Xu, PhD, Kohei Kume, PhD, Gang Xiao, PhD and Markus Müschen, MD

**Monday, December 12**
6:00 – 8:00 PM
**Location:** Hall D (Ernest N. Morial Convention Center)

**641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III**

**4420 Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression**

**Authors:** Lisa Brandmeier, MSc, Veronika Ecker, Martina Stumpf, Piero Giansanti, Aida Varela Moreira, Lisa Pfeuffer, Marcel Fens, Junyan Lu, Bernhard Küster, PhD, Thomas Englertner, Simon Heidegger, Ingo Ringshausen, Thorsten Zenz, Clemens-Martin Wendtner, Markus Müschen, MD, Jürgen Ruland, and Maike Buchner

**Monday, December 12**
6:00 – 8:00 PM
**Location:** Hall D (Ernest N. Morial Convention Center)

**612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III**

**4003 Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant**

**Authors:** Adam J. de Smith, PhD, Lara Wahlster, MD, PhD, Soyoung Jeon, BSc, Fulong Yu, PhD, Susan Black, Steven Gazal, PhD, Nicholas Mancuso, PhD, Catherine Metayer, MD, PhD, **Xiaomei Ma, PhD**, Joseph L. Wiemels, PhD, Charleston W. K. Chiang, PhD and Vijay G. Sankaran, MD, PhD

**Monday, December 12**
6:00 – 8:00 PM
**Location:** Hall D (Ernest N. Morial Convention Center)

**101. Red Cells and Erythropoiesis, Excluding Iron: Poster III**

**3640 BMI1 Regulates Proliferation of Human Late-Stage Erythroid Progenitors**

**Authors:** Jayme L. Olsen, PhD, Kathleen E. McGrath, PhD, Kristin Murphy, PhD, Taylor Schofield, Michael Getman, MS, Mohandas Narla, DSc, Lionel Blanc, PhD, **Vincent P Schulz, PhD, Patrick G. Gallagher, MD**, Laurie A. Steiner, MD and James Palis, MD

**Monday, December 12**
6:00 – 8:00 PM
**Location:** Hall D (Ernest N. Morial Convention Center)

**616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III**

**4080 Umbrella Trial in Myeloid Malignancies: The Myelomatch National Trials Network Precision Medicine Initiative**

**Authors:** Richard F. Little, MD, MPH, Megan Othus, PhD, Sarit Assouline, Sherry Ansher, PhD, Ehab L. Atallah, MD, R. Coleman Lindsley, Boris Freidlin, PhD, Steven D. Gore, MD, Lyndsay Harris, MD, Christopher S. Hourigan, MD, S. Percy Ivy, MD, Shahhanawaz Jiwani, MD, PhD, MS, Erin Langan, Selina M. Luger, MD, FRCPC, Laura C. Michaelis, MD, Olatoyosi Odenike, MD, David Patton, Miguel-Angel Perales, MD, Jerald P. Radich, MD, Bhanu Ramineni, MS, MS, Jesse J. Salk, MD, PhD, Patrick Stiff, MD, Wendy Stock, MD, Richard M. Stone, MD, Geoffrey L. Uy, MD, P. Mickey Williams, PhD, Brent L. Wood, MD PhD, Katherine H Worthington, PhD, Laura M
Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III

4245 Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Authors: Pamela B. Allen, MD, Subir Goyal, PhD, Swaminathan P. Iyer, MD, Sai Talluru, MD, Auris Huen, MD, PharmD, Irl Brian Greenwell, MD, Jane Scribner, MD, Shel Speegle, MS, Tim Niyogusaba, BA, Sunil Rangarajan, MD, Amitkumar Mehta, MD, Colin B. O’Leary, MA, Anne W. Beaven, MD, Jeffrey M. Switchenko, PhD, MS, Amy Ayers, MPH, Safiyyah Bhatti, Shalini Krishnasamy, MD, Pierluigi Porcu, MD, Tarsheen Sethi, MD, MBBS, MSc, Francine M. Foss, MD, Mary Jo Lechowicz, MD and Sima Rozati, MD, PhD

Monday, December 12
6:00 – 8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)

652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III

4523 Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Authors: Andrea Angioi, MD, Moritz Binder, MD, Nelson Leung, MD, Frank Bridoux, MD, PhD, Camille Cohen, David Dingli, MD, PhD, Angela Dispenzieri, MD, Parikshit Duriseti, MD, Roberta Fenoglio, Amie Fonder, PA-C, Morie A. Gertz, MD, MACP, Ronald Go, MD, Wilson I. Gonsalves, MD, Suzanne R. Hayman, MD, Miriam A. Hobbs, APRN, CNP, DNP, Yi L. Hwa, NP, Prashant Kapoor, MD, Bertrand Knebelmann, Taxiarchis Kourelis, MD, Shaji K Kumar, MD, Robert A. Kyle, MD, Martha Q. Lacy, MD, Nicola Lepori, Yi Lin, MD, PhD, Shveta Motwani, MD, Eli Muchtar, MD, Samih Nasr, MD, Antonello Pani, Dario Roccatello, Virginie Royal, MD, Paul Sanders, Stephan Troyanov, MD, Christopher P. Venner, Rahma M Warsame, MD, Niloufarsadat Yarandi, MD and S. Vincent Rajkumar, MD